Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.55 USD
+0.30 (9.23%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.54 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
STRO 3.55 +0.30(9.23%)
Will STRO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STRO
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Other News for STRO
Sutro Biopharma initiates REFRaME-P1 trial of luvelta in AML
Sutro Biopharma initiates REFRaME-P1 trial of luvelta in AML
Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Sutro Biopharma management to meet with Truist
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRĪ± Remain Viable?